^
    18h
    A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=90, Not yet recruiting, Cogent Biosciences, Inc.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 positive • HR positive • HER-2 negative • PIK3CA mutation • HR positive + HER-2 negative
    19h
    Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease (clinicaltrials.gov)
    P2, N=145, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    19h
    Pre-operative Therapy in Breast Cancer (clinicaltrials.gov)
    P=N/A, N=488, Recruiting, RenJi Hospital | Trial primary completion date: Nov 2025 --> Nov 2030
    Trial primary completion date
    19h
    De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (clinicaltrials.gov)
    P3, N=1670, Recruiting, NRG Oncology | Trial primary completion date: Jan 2026 --> Apr 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • letrozole • exemestane
    20h
    Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, The Methodist Hospital Research Institute
    New P2 trial
    |
    Valcyte (valganciclovir)
    20h
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) (clinicaltrials.gov)
    P2, N=111, Recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HR positive
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Herceptin (trastuzumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin • trastuzumab rezetecan (SHR-A1811)
    20h
    NeoChemoPRT: Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    23h
    Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=280, Recruiting, SystImmune Inc. | Trial completion date: Aug 2027 --> Apr 2029 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • HER-2 mutation • HER-2 expression
    |
    trastuzumab brengitecan (BL-M07D1)
    23h
    Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype (clinicaltrials.gov)
    P3, N=248, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • PGR positive
    |
    trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)
    23h
    A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Recruiting, Ottimo Pharma Limited | Not yet recruiting --> Recruiting
    Enrollment open
    24h
    Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (clinicaltrials.gov)
    P=N/A, N=64, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    1d
    MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov)
    P3, N=493, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Verzenio (abemaciclib) • letrozole • anastrozole